Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$25.77
−$0.72 · -2.72%
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Previous close
$25.77
−$0.72 · -2.72%
After-hours
$25.77
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Day range
Current $25.77
52-week range
Current $25.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
41
Mixed
Risk
45
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
Day range
Current $25.77
52-week range
Current $25.77
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 95.13M USD | 59.82M USD | 27.81M USD | 7.63M USD |
| Cost of goods sold | 46.26M USD | 35.61M USD | 27.45M USD | 18.28M USD |
| Gross profit | 48.86M USD | 24.21M USD | 362K USD | −10.65M USD |
| Research and development | 19.48M USD | 15.65M USD | 15.49M USD | 15.76M USD |
| Selling, general, and administrative | 164.12M USD | 114.94M USD | 69.94M USD | 54.01M USD |
| Operating expenses | 183.6M USD | 130.59M USD | 85.43M USD | 69.77M USD |
| Interest income | 8.35M USD | 3.2M USD | — | — |
| Interest expense | 7.55M USD | 7.73M USD | 6.23M USD | 5.63M USD |
| Depreciation and amortization | 8.71M USD | 7.97M USD | 11.56M USD | 4.86M USD |
| Operating income | −134.74M USD | −106.38M USD | −85.06M USD | −80.42M USD |
| Net income | −131.61M USD | −113.81M USD | −94.12M USD | −84.24M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI23.88M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM18.72M0.02%77.7B USD0.19%$277.57-0.05%
iShares Russell 2000 Growth ETFIWO6.56M0.05%14.04B USD0.24%$353.47-0.53%
First Trust Small Cap Growth AlphaDEX FundFYC6.41M0.48%1.77B USD0.70%$113.82-0.39%
Vanguard Extended Market ETFVXF5.81M0.01%95.4B USD0.05%$233.13-0.15%
Schwab U.S. Small-Cap ETFSCHA4.65M0.02%21.7B USD0.03%$32.66+0.15%
iShares U.S. Medical Devices ETFIHI4.32M0.12%3.53B USD0.37%$51.10+0.29%
Vanguard Russell 2000 ETFVTWO3.97M0.02%18B USD0.06%$112.1-0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOFirst Trust Small Cap Growth AlphaDEX FundFYCVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares U.S. Medical Devices ETFIHIVanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
